FY2026 Earnings Forecast for Amgen Issued By Leerink Partnrs

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Leerink Partnrs lowered their FY2026 EPS estimates for shares of Amgen in a research report issued to clients and investors on Wednesday, October 30th. Leerink Partnrs analyst D. Risinger now expects that the medical research company will post earnings of $18.56 per share for the year, down from their prior estimate of $18.66. The consensus estimate for Amgen’s current full-year earnings is $19.48 per share. Leerink Partnrs also issued estimates for Amgen’s FY2027 earnings at $18.71 EPS.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 181.58% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the company earned $4.96 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year.

A number of other brokerages also recently weighed in on AMGN. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $320.00 to $335.00 in a research note on Wednesday, August 7th. Barclays boosted their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. TD Cowen increased their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $319.99 on Friday. The stock’s 50-day simple moving average is $324.66 and its two-hundred day simple moving average is $314.82. Amgen has a twelve month low of $260.52 and a twelve month high of $346.85. The firm has a market capitalization of $171.94 billion, a P/E ratio of 40.99, a P/E/G ratio of 2.84 and a beta of 0.61. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.81%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the 3rd quarter worth $25,000. Hershey Financial Advisers LLC bought a new position in Amgen in the 2nd quarter worth $30,000. nVerses Capital LLC bought a new stake in Amgen during the second quarter valued at about $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen in the second quarter worth about $33,000. Finally, Matrix Trust Co purchased a new stake in Amgen during the 3rd quarter valued at approximately $36,000. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.